当前位置: 首页 > 期刊 > 《中国现代医生》 > 202013
编号:13480063
安罗替尼联合恩度或顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床研究(4)
http://www.100md.com 2020年5月5日 《中国现代医生》 202013
     [13] 姜子瑜,秦叔逵.重组人血管内皮抑素治疗恶性浆膜腔积液的研究进展[J].臨床肿瘤学杂志,2010,15(10):937-943.

    [14] 郑俊琼,詹颖,廖雪燕,等.重组人血管内皮抑素联合顺铂局部治疗恶性胸腹腔积液的临床观察[J].中国现代医生,2015,18(53): 19-21.

    [15] 斯晓燕,王汉萍,张晓彤,等.安罗替尼治疗晚期非小细胞肺癌16例临床分析[J].中华内科杂志,2018,57(11):830-834.

    [16] Han BH,Li K,Wang QM,et al. Effect of anlotinib as a thirdlineor further treatment on overall survival of patients with advanced non-small cell lung cancer:The ALTER 0303 phase 3 randomized clinical trial[J/OL].JAMA Oncol,2018,4(11):1569-1575.

    [17] 苏雨栋,孟昭婷,徐晓燕,等.安罗替尼治疗KRAS突变型晚期肺腺癌1例[J].中国肺癌杂志,2018,21(5): 428-430.

    [18] Si XY,Zhang L,Wang HP,et al.Quality of life results from arandomized,double-blinded, placebo-controlled,multi-center phaseIII trial of anlotinib in patients with advanced non-small cell lung cancer[J].Lung Cancer,2018, 122:32-37.

    [19] Han BH,Li K,Zhan YZ,et al.Anlotinib as a third-line therapyin patients with refractory advanced non-small-cell lung cancer:Amulticentre, randomised phase II trial(ALTER0302)[J/OL].Br J Cancer,2018,118(5):654-661.

    (收稿日期:2020-02-18), http://www.100md.com(郑文慧 米虽才 陈志明)
上一页1 2 3 4